Citing a need to shift resources to different research and development projects, Merck said it will eliminate 500 U.S. jobs by Jan. 3, according to EndPoints News.
Most of the affected roles include sales employees and commercial teams at its Pennsylvania headquarters. It also includes job cuts in New Jersey and employees working remotely from across the U.S.
"This is not a new restructuring effort; these changes are part of ongoing companywide efforts to sharpen Merck's focus on innovative research and development that addresses significant unmet medical needs and on our best opportunities for growth," the drugmaker told the pharmaceutical industry news website.
Affected employees can apply for open jobs within Merck, or they will be offered a separation package.
The drugmaker said it plans to add jobs in oncology and other growth areas.